Publications by authors named "Francisco Giron-Fernandez-Crehuet"
Introduction And Objectives: Metastatic Crohn's disease (MCD) is an extraintestinal manifestation of Crohn's disease, with biopsy as fundamental diagnostic tool. There are few references to MCD in children, with a 0.5-1% estimated incidence in adults.
View Article and Find Full Text PDFUlcerative colitis (UC) is defined as a chronic inflammatory condition causing continuous mucosal inflammation of the colon without granulomas on biopsy. It affects the rectum, and, to a variable extent, the colon in continuity and is characterized by a relapsing and remitting course. Oral 5-aminosalicylic acid (5-ASA) regimens are recommended as first-line induction therapy for mild to moderately active pediatric UC and for maintenance of remission regardless of other initial treatments.
View Article and Find Full Text PDFBackground: Azathioprine [AZA] and mercaptopurine [MP] are recommended for maintenance of steroid-free remission in children with Crohn`s disease [CD]. Azathioprine-induced pancreatitis, an idiosyncratic and major side effect, has been considered as an absolute contraindication for the use of a second thiopurine in IBD patients.
Materials And Methods: We describe two children with CD in whom MP were successfully trialled after a confirmed azathioprine-induced pancreatitis, being well tolerated in both cases.
Introduction: The conventional 24-hour pH monitoring is the gold standard for the diagnosis of gastro-esophageal reflux (GER), a possible cause of Apparent Life Threatening Episodes (ALTE). However, multichannel intraluminal impedance (MII) may provide advantages.
Objectives: Comparison of the results of MII and pH monitoring in patients undergoing MII-pH monitoring in the 3-year study period because of having suffered from ALTE.
Article Synopsis
- This study aims to evaluate the effectiveness and safety of adalimumab (ADA) in treating children with Crohn's disease (CD) by focusing on clinical remission and intestinal inflammation.
- Sixteen children diagnosed with CD received ADA treatment, showing a significant reduction in disease activity and inflammation levels after 12 weeks, as measured by the Pediatric Crohn's Disease Activity Index (PCDAI) and fecal calprotectin (FC).
- While ADA was effective for most patients, some adverse events occurred, including one lymphoma case, suggesting that the benefits of treatment must be carefully balanced with potential risks, and further research is needed for long-term outcomes.